Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Arcagy Gineco
Sponsor

Arcagy Gineco

France 1 Parvis Notre Dame Place Jean Paul Ii, 75004 Paris, France

About the sponsor

The sponsor’s research activity is centered on advanced and recurrent ovarian cancer, including platinum-sensitive recurrent disease, poor-prognosis ovarian cancer, and cancers of the tubal and peritoneal origin. Its funded studies also address treatment after surgery and maintenance strategies in patients with residual risk of relapse.

  • Maintenance therapy in recurrent ovarian cancer
  • Platinum-sensitive recurrence
  • Advanced ovarian, tubal, and peritoneal cancer
  • Poor prognostic ovarian cancer

Research in this area reflects a strong focus on chemotherapy combinations, anti-angiogenic treatment, PARP inhibition, and immunotherapy for ovarian malignancies.

About Specializations

Arcagy Gineco runs clinical trials in conditions such as Ovarian cancer, Endometrial cancer, Peritoneal sarcoma, Ovarian epithelial cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

7 clinical trials

Ovarian cancer

Recruiting

Study of Pembrolizumab with Etoposide and Cisplatin for First-Line Treatment in Patients with Small Cell Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Arcagy Gineco

Peritoneal sarcoma+5

Recruiting

Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcagy Gineco

Ovarian cancer

Recruiting

Study of Paclitaxel, Carboplatin, and Bevacizumab with Niraparib for Patients with Advanced Ovarian, Tubal, or Peritoneal Cancer After Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcagy Gineco

Endometrial cancer+2

Recruiting

Study on Dostarlimab and Niraparib for Patients with Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Arcagy Gineco

Ovarian cancer

Not yet recruiting

Phase I/II Study of ubamatamab plus drug combination in patients with ovarian cancer who have poor response to first‑line chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcagy Gineco

Endometrial cancer

Not yet recruiting

Study Comparing Chemotherapy Alone to Dostarlimab, Paclitaxel, and Carboplatin for Patients with Advanced or Metastatic Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Arcagy Gineco

Ovarian cancer+1

Not recruiting

Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:MPS-102
  • Sponsor:Arcagy Gineco

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.